Clinical Decision-Making for Drug-Resistant Tuberculosis
Medical graduates working in the field of drug-resistant tuberculosis (DR TB) are invited to join this 10-week blended learning course on the clinical aspects and decision-making of DR TB diagnosis and care.
Deadline: 15 December 2023
5 ECTS Credits
Drug-resistant tuberculosis (DR-TB) is an important challenge for clinicians. With the introduction of molecular diagnostic tests, such as the Xpert MTB/RIF assay and Line Probe Assays, the notification of DR-TB is increasing and the time to diagnosis can be shortened, allowing earlier treatment initiation. Shorter treatment regimens (STR) have been recommended by WHO since 2016, thus simplifying treatment for patients and National TB Programs alike. Access to bedaquiline, delamanid, linezolid, and clofazimine is increasing and guidelines are adapted frequently. Clinicians require training in the use of these new diagnostic tools, the interpretation of guidelines, and in making informed choices for treatment initiation and monitoring and in adequate and timely clinical decision making.
For this course, we have a partnership with: Damien Foundation, MSF, University Hospital Leuven, Nottingham Trent University and PATH Ukraine.
This blended course offers interdisciplinary and interactive training on clinical aspects of DR TB diagnosis and care. It consists of an 11-week online training (includes a break of 3 weeks) followed by 2 weeks face-to-face (includes 1 public holiday).
Student Investment Time during the online part: 10 hours per week = 80 hours.
Student Investment Time during the face-to-face part: 7,5 hours per day = 67,5 hours.
IMPORTANT: The course is offered in a "hybrid" way. This means that participants can follow the face-to-face part online, in case they cannot travel.
After completion of the course, participants should be able to:
- Characterize the problems with DR-TB in their country in terms of occurrence, diagnosis and treatment, using available data.
- Balance harm and benefit of clinical decisions in the field of DR-TB diagnosis and treatment.
- Formulate evidence-based recommendations for DR-TB diagnosis and treatment for case studies presented by participants and faculty.
- Contextualise these evidence-based recommendations to their own setting.
- Formulate recommendations to prevent the emergence of DR during treatment and preserve treatment options in their own context.